in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Wacker, XL-protein sign cooperation agreement to produce biopharmaceuticals
7:38 AM MST | November 5, 2012 | Deepti Ramesh
Wacker says that its Wacker Biotech (Jena, Germany) subsidiary and XL-protein (Freising, Germany), a privately owned biopharmaceutical company, have signed an agreement to collaborate more intensely on the production of PASylated therapeutic proteins. Through this collaboration, Wacker and its customers will gain access to XL-protein’s PASylation platform. The PASylation technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly, Wacker says. In a recent...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee